“
“Episodes of bleeding in people with haemophilia (PWH) are associated with reduced activity and limitations in physical performance. Within the scope of the ‘Haemophilia & Exercise Project’ (HEP) PWH were

trained in a sports therapy programme. Aim of this study was to investigate subjective and objective physical performance in HEP-participants after 1 year training. Physical performance of 48 adult PWH was compared before and after sports therapy subjectively (HEP-Test-Q) and objectively regarding mobility (range of motion), strength and coordination (one-leg-stand) and endurance (12-min walk test). Sports therapy included an independent home training that had previously been trained in several collective sports camps. Forty-three

controls without GSK126 haemophilia and without training were compared to PWH. Of 48 PWH, 13 selleck kinase inhibitor performed a regular training (active PWH); 12 HEP-participants were constantly passive (passive PWH). Twenty-three PWH and 24 controls dropped out because of incomplete data. The activity level increased by 100% in active PWH and remained constant in passive PWH, and in controls (P ≤ 0.05). Only mobility of the right knee was significantly improved in active PWH (+5.8 ± 5.3°) compared to passive PWH (−1.3 ± 8.6°). The 12-min walk test proved a longer walking distance for active PWH (+217 ± 199 m) compared to controls (−32 ± 217 m). Active PWH reported a better subjective physical performance in the HEP-Test-Q domains ‘strength & coordination’, ‘endurance’ and in the total score (+9.4 ± 13.8) compared to passive PWH (−5.3 ± 13.5) and controls (+3.7 ± 7.5). The ‘mobility’-scale and one-leg-stand remained unchanged. Sports therapy increases the activity level and physical performance of PWH, whereby selleck screening library objective effects do not always correspond with subjective assessments. “
“Summary.  The classification of haemophilia originates from 1950s and has been adopted unchallengedly by the ISTH in 2001. The aim of this study was: does the current

classification compare onset of bleeding and age at first treatment, as well as annual joint bleeding frequency according to baseline FVIII activity? Data on age and reason of diagnosis, onset of treatment, onset of bleeding and bleeding frequency from 411 patients with haemophilia A born after 1970 were collected. Data were analysed according to base-line FVIII activity levels. Age at diagnosis, onset of bleeding and start of treatment according to FVIII activity were compared with the current classification. Overall, the distinction between severe and non-severe haemophilia was clear. The distinction between mild and moderate haemophilia was more difficult, mostly due to the wide variability in the group of patients with moderate haemophilia.

“
“Episodes of bleeding in people with haemophilia (PWH) are associated with reduced activity and limitations in physical performance. Within the scope of the ‘Haemophilia & Exercise Project’ (HEP) PWH were

trained in a sports therapy programme. Aim of this study was to investigate subjective and objective physical performance in HEP-participants after 1 year training. Physical performance of 48 adult PWH was compared before and after sports therapy subjectively (HEP-Test-Q) and objectively regarding mobility (range of motion), strength and coordination (one-leg-stand) and endurance (12-min walk test). Sports therapy included an independent home training that had previously been trained in several collective sports camps. Forty-three

controls without buy Maraviroc haemophilia and without training were compared to PWH. Of 48 PWH, 13 Ceritinib performed a regular training (active PWH); 12 HEP-participants were constantly passive (passive PWH). Twenty-three PWH and 24 controls dropped out because of incomplete data. The activity level increased by 100% in active PWH and remained constant in passive PWH, and in controls (P ≤ 0.05). Only mobility of the right knee was significantly improved in active PWH (+5.8 ± 5.3°) compared to passive PWH (−1.3 ± 8.6°). The 12-min walk test proved a longer walking distance for active PWH (+217 ± 199 m) compared to controls (−32 ± 217 m). Active PWH reported a better subjective physical performance in the HEP-Test-Q domains ‘strength & coordination’, ‘endurance’ and in the total score (+9.4 ± 13.8) compared to passive PWH (−5.3 ± 13.5) and controls (+3.7 ± 7.5). The ‘mobility’-scale and one-leg-stand remained unchanged. Sports therapy increases the activity level and physical performance of PWH, whereby click here objective effects do not always correspond with subjective assessments. “
“Summary.  The classification of haemophilia originates from 1950s and has been adopted unchallengedly by the ISTH in 2001. The aim of this study was: does the current

classification compare onset of bleeding and age at first treatment, as well as annual joint bleeding frequency according to baseline FVIII activity? Data on age and reason of diagnosis, onset of treatment, onset of bleeding and bleeding frequency from 411 patients with haemophilia A born after 1970 were collected. Data were analysed according to base-line FVIII activity levels. Age at diagnosis, onset of bleeding and start of treatment according to FVIII activity were compared with the current classification. Overall, the distinction between severe and non-severe haemophilia was clear. The distinction between mild and moderate haemophilia was more difficult, mostly due to the wide variability in the group of patients with moderate haemophilia.

1-6 It can be difficult to appraise the relative contribution of comorbidities and MHE on CD without excluding patients with JQ1 concentration comorbidities. However, such exclusion may decrease representativity in daily clinical practice. For this reason, although we believe that CD, in most patients in our study, mainly corresponds to MHE, in the absence of well-established criteria,5, 7 CD in cirrhosis is more appropriate to describe

our population and we preferred therefore to use this term in our study. CD in cirrhosis has become more relevant in recent years because it has been associated with overt HE,2 mortality,1, 8 worsening in quality of life, and deterioration in daily functioning.1, 3, 9 MHE has a negative effect on driving, and these patients are more predisposed to traffic accidents and violations.10, 11 Because CD impairs attention and reaction capability,1, 4 it likely also predisposes patients with cirrhosis to fall, as we observed in a retrospective assessment.12 However, this association has not yet been

prospectively evaluated. Falls are particularly important in patients with cirrhosis HIF activation because their risk of fracture is higher than that in the general population.13 This risk has been attributed to a decrease in bone mass resulting from malnutrition, hypogonadism, and liver insufficiency,14 but it could also be a consequence of CD-related falls.12 Moreover, traumas in patients with cirrhosis are a significant cause of complications and mortality.15 In addition to the negative consequences for the patient, falls selleck products and fractures have implications for the patient’s relatives and are an economic and social burden for the community.16 The Psychometric Hepatic Encephalopathy Score (PHES) consists of a battery of five paper-pencil tests specifically developed for the diagnosis of MHE.2, 4 PHES is scored from the comparison with nomograms in healthy controls; each negative point represents one standard deviation (1 SD) below the mean of the reference population. A result on the PHES <−4

has been proposed for the diagnosis of MHE.2, 4 We designed this study to assess whether, in addition to detecting a cognitive disturbance, the PHES could identify those patients with a higher risk for falls. AUROC, area under the receiver operating characteristics curve; BMI, body mass index; CD, cognitive dysfunction; CFF, critical flicker frequency; HE, hepatic encephalopathy; MAP, mean arterial pressure; MELD: model for end-stage liver disease score; MHE, minimal hepatic encephalopathy; PHES, Psychometric Hepatic Encephalopathy Score; SD, standard deviation; SSRIs, selective serotonin-reuptake inhibitors; TIPS, transjugular intrahepatic portosystemic shunt; TUG, Timed Up-and-Go Test.

In this issue of HEPATOLOGY, Kahraman et al.13 report that hepatic NK cells, expression of NK cell–associated cytotoxic mediators (such as tumor necrosis factor–related apoptosis-inducing ligand [TRAIL]), NKG2D, and MICA/B messenger RNAs in the liver are significantly elevated in nonalcoholic steatohepatitis (NASH) and, to a lesser extent, in nonalcoholic fatty liver (NAFL), when compared to normal healthy control livers. Immunohistochemical analyses reveal

that MICA/B proteins are detected from hepatocytes in patients with NASH and NAFL. Moreover, the expression of MICA/B messenger RNAs are positively correlated with NAS score and hepatocyte apoptosis in NASH. These findings suggest that the MICA/B protein levels are up-regulated in hepatocytes from patients with NASH through mechanisms that have yet to be identified. selleck screening library This is then followed by activation of hepatic NK cells that release TRAIL as a means of killing hepatocytes, and thereby inducing hepatocelluar damage in these patients. It is not clear whether NK cells only kill MICA/B-positive hepatocytes or if they also kill MICA/B-negative cells. This could be confirmed by performing double-staining to determine whether MICA/B protein and terminal deoxynucleotidyl transferase–mediated dUTP nick-end find more labeling (TUNEL+) hepatocytes are colocalized. Whereas the molecular mechanism underlying up-regulation of hepatic MICA/B

in NASH and NAFL patients was not explored in the study by Kahraman et al.,13 it has been well documented that expression of NKG2D ligands are up-regulated through a variety of stimuli that have been collectively termed “cellular stress”, such as cellular transformation, viral infection, and/or DNA damage.2, 3 It is known that fat accumulation can generate oxidative stress-induced DNA damage in hepatocytes,14 which may contribute to the up-regulation of hepatic MICA/B this website in patients with NASH and NAFL. Interestingly, Kahraman et al.13 also show that levels of MICA/B messenger RNAs correlate positively with stage of fibrosis, suggesting that MICA/B also contribute to the progression of liver fibrosis. However, recent studies using

murine models of liver fibrosis suggest that the NKG2D-ligand interaction triggers the killing of activated hepatic stellate cells (HSCs) by NK cells through a TRAIL-dependent mechanism, thereby inhibiting liver fibrosis.15, 16 Liver fibrosis is a common scarring response to virtually all forms of chronic liver injury and is characterized by HSC activation and accumulation of collagen in the liver. In normal healthy livers, HSCs are quiescent, storing large amounts of vitamin A (retinol). During liver injury or culturing on plastic dishes, HSCs become activated and differentiate into myofiboblast cells that produce collagen. Activated HSCs can also become senescent during chronic liver injury or after 9–15 passages in vitro.

Key Word(s): 1. CHB; 2. trough concentration; 3. HPLC-MS/MS; 4. ADV,TDF; Presenting Author: PRAVEEN KUMAR Additional Authors: RAJIV BAIJAL, DEEPAK AMARAPURKAR, NIMISH SHAH, MRUDUL DHAROD, SANDEEP KULKARNI, DEEPAK GUPTA, SOHAM DOSHI Corresponding Author: PRAVEEN KUMAR Affiliations: Indian railways; Indian Railways; Bombay Hospital Objective: To study the safety profile and response to interferon/peg-interferon and ribavirin in Hepatitis C patients

at two tertiary care centres in Mumbai, India AZD1208 cell line over 3 years. Methods: All patients of hepatitis C seen at Jagivan Ram Hospital and Bombay Hospital, Mumbai from January 2010 to January 2013 were retrospectively evaluated for their clinical profile of hepatitis C, HCV RNA levels and HCV genotype, treatment given, RVR, EVR, ETVR, SVR on therapy, and complications of therapy. Results: Out of 213 patients evaluated 127(59.62%)were males. Mean age was 49.72 +/- 12.07 years. 96 (45.07%) patients had chronic hepatitis C, 113(53.05%)patients had cirrhosis and 4(1.88%) patients had HCC at diagnosis. 48(26.37%) patients had genotype 1 HCV, 120(65.93%) patients had genotype 3, 14 patients had genotype 2&4. Genotype status of 31 patients was not known.97(45.53%)patients out of 213 were started on treatmnt

for Hepatitis C. Out of 97 patients 91 were treated with pegylated interferon and ribavirin and 6 patients received plain interferon and ribavirin. Major reasons for not starting therapy were decompensated cirrhosis, severe cytopenia’s and affordability. Out of total 97 patients started on treatment 12 were selleck products lost to follow up, 18 patients had

to discontinue treatment of which 11 were nonresponders and 7 did not tolerate therapy in form of severe cytopenias(2), worsening liver function(3) and severe bodyaches(2).RVR was achieved in 55(68.75%) patients (52- pegylated interferon and 3- plain interferon)EVR was achieved in 71(87.65%) patients (68- pegylated interferon and 3- plain interferon)There were 16 patients who didn’t achieve RVR, but subsequently achieved EVR.61/97 paients selleckchem completed therapy. SVR was achieved in 44/61(80%) patients.[42(79.25%)-pegylated interferon and 2(100%)-plain interferon]. [8(72.73%)-genotype1, 30(78.95%)-genotype3,6(100%)-genotype others][22(84.6%) chronic hepatitis, 22(75.8%) cirrhosis].Complications seen on therapy were hypothyroidism(5), anemia(5), leucopenia(2), psychological complications(20) with severe depression(1) and worsening liver functions (3). Conclusion: Out of 213 patients only 97 patients could be started on treatment. Only 61/97 patients completed therapy. SVR was achieved in 44 patients(20 % of all patients but 80% of patients who completed therapy). Key Word(s): 1. Chronic hepatitis C; 2. Interferon; 3. Efficacy; 4.

Key Word(s): 1. CHB; 2. trough concentration; 3. HPLC-MS/MS; 4. ADV,TDF; Presenting Author: PRAVEEN KUMAR Additional Authors: RAJIV BAIJAL, DEEPAK AMARAPURKAR, NIMISH SHAH, MRUDUL DHAROD, SANDEEP KULKARNI, DEEPAK GUPTA, SOHAM DOSHI Corresponding Author: PRAVEEN KUMAR Affiliations: Indian railways; Indian Railways; Bombay Hospital Objective: To study the safety profile and response to interferon/peg-interferon and ribavirin in Hepatitis C patients

at two tertiary care centres in Mumbai, India buy PF-01367338 over 3 years. Methods: All patients of hepatitis C seen at Jagivan Ram Hospital and Bombay Hospital, Mumbai from January 2010 to January 2013 were retrospectively evaluated for their clinical profile of hepatitis C, HCV RNA levels and HCV genotype, treatment given, RVR, EVR, ETVR, SVR on therapy, and complications of therapy. Results: Out of 213 patients evaluated 127(59.62%)were males. Mean age was 49.72 +/- 12.07 years. 96 (45.07%) patients had chronic hepatitis C, 113(53.05%)patients had cirrhosis and 4(1.88%) patients had HCC at diagnosis. 48(26.37%) patients had genotype 1 HCV, 120(65.93%) patients had genotype 3, 14 patients had genotype 2&4. Genotype status of 31 patients was not known.97(45.53%)patients out of 213 were started on treatmnt

for Hepatitis C. Out of 97 patients 91 were treated with pegylated interferon and ribavirin and 6 patients received plain interferon and ribavirin. Major reasons for not starting therapy were decompensated cirrhosis, severe cytopenia’s and affordability. Out of total 97 patients started on treatment 12 were EX 527 order lost to follow up, 18 patients had

to discontinue treatment of which 11 were nonresponders and 7 did not tolerate therapy in form of severe cytopenias(2), worsening liver function(3) and severe bodyaches(2).RVR was achieved in 55(68.75%) patients (52- pegylated interferon and 3- plain interferon)EVR was achieved in 71(87.65%) patients (68- pegylated interferon and 3- plain interferon)There were 16 patients who didn’t achieve RVR, but subsequently achieved EVR.61/97 paients learn more completed therapy. SVR was achieved in 44/61(80%) patients.[42(79.25%)-pegylated interferon and 2(100%)-plain interferon]. [8(72.73%)-genotype1, 30(78.95%)-genotype3,6(100%)-genotype others][22(84.6%) chronic hepatitis, 22(75.8%) cirrhosis].Complications seen on therapy were hypothyroidism(5), anemia(5), leucopenia(2), psychological complications(20) with severe depression(1) and worsening liver functions (3). Conclusion: Out of 213 patients only 97 patients could be started on treatment. Only 61/97 patients completed therapy. SVR was achieved in 44 patients(20 % of all patients but 80% of patients who completed therapy). Key Word(s): 1. Chronic hepatitis C; 2. Interferon; 3. Efficacy; 4.

It was found that miR-335, which is harbored within an intron of its protein-coding host gene, MEST, was down-regulated by PS-341 molecular weight aberrant promoter hypermethylation. The expression levels of miR-335 significantly correlated with those of MEST, supporting the notion that the intronic miR-335 is co-expressed with its host gene. The level of miR-335/MEST methylation was significantly higher in 18 (90%) out of 20 primary HCC tumors, compared to their non-tumor tissue counterparts (P<0. 001). The expression level of miR-335 was significantly lower in 25 (78%) out of 32 primary

HCC tumors, compared to their non-tumorous tissue counterparts (P=0. 001). Since miR-335 was identified as a metastasis suppressor miRNA in breast cancer, we examined the relationship between the expression levels of miR-335 and the presence of distant metastasis in these 32 primary HCCs. The expression

level of miR-335 was significantly lower in HCC tumors with distant metastasis than in those without distant metastasis (P=0. 02). In conclusion, our results indicate that expression of miR-335 is reduced by aberrant DNA methylation in HCC. Disclosures: Kohichiroh Yasui – Grant/Research Support: AstraZeneca K. K., CHUGAI Pharmaceutical Co., Ltd., Dainippon Sumitomo Pharma Co., Ltd., Eisai Co., Ltd., FUJIFILM Medical Co., Ltd., Merck Serono, MSD K. K., Otsuka Pharmaceutical Co., Ltd. The following people have nothing to disclose: Osamu Dohi, Masayasu Jo, Yoshito Itoh Thioredoxin domain-containing protein 5 (TXNDC5) has been found to be associated AZD8055 datasheet with cancer development and growth. We investigated whether TXNDC5 gene polymorphisms are associated with hepatocellular carcinoma check details (HCC) in Korean male population. Seven SNPs were selected based on minor allele frequency (>0. 5). The SNPs consisted of three exonic (rs8643, rs7764128 and rs1043784) and four intronic SNPs (rs1225944, rs1225943, rs1225945 and rs1225958). We selected and assessed these SNPs in 160 HCC patients and 178 controls. Genetic data were analyzed using SNPAnalyzer Pro, SNPStats, and Haploview programs. Two SNPs of the TXNDC5 gene were found to be associated with the risk of HCC development.

The genotype frequency of rs1225944 was associated with HCC in the recessive model (CC/CT vs. TT, p=0. 43, Fisher’s exact p=0. 032, 〇R-0. 54, 95% CI=0. 112. 71). The genotype frequency of rs1225943 was associated with HCC in the codominant 2 (AA vs. CC, p=0. 07, Fisher’s exact p=0. 001, 〇R=0. 23, 95% CI=0. 05-1. 10), recessive (AA/AC vs. CC, p=0. 044, Fisher’s exact p=0. 001, 〇R=0. 25, 95% CI=0. 05-1. 17), and log-additive models (p=0. 08, Fisher’s exact p=0. 002, 〇R-0. 68, 95% CI=0. 44-1. 05). The haplotype CA and TC, consisting of rs1229544 and rs1225943, demonstrated a significant association with HCC. Our results suggest that TXNDC5 polymorphisms could be concerned with the development of HCC in the Korean male population.

It was found that miR-335, which is harbored within an intron of its protein-coding host gene, MEST, was down-regulated by click here aberrant promoter hypermethylation. The expression levels of miR-335 significantly correlated with those of MEST, supporting the notion that the intronic miR-335 is co-expressed with its host gene. The level of miR-335/MEST methylation was significantly higher in 18 (90%) out of 20 primary HCC tumors, compared to their non-tumor tissue counterparts (P<0. 001). The expression level of miR-335 was significantly lower in 25 (78%) out of 32 primary

HCC tumors, compared to their non-tumorous tissue counterparts (P=0. 001). Since miR-335 was identified as a metastasis suppressor miRNA in breast cancer, we examined the relationship between the expression levels of miR-335 and the presence of distant metastasis in these 32 primary HCCs. The expression

level of miR-335 was significantly lower in HCC tumors with distant metastasis than in those without distant metastasis (P=0. 02). In conclusion, our results indicate that expression of miR-335 is reduced by aberrant DNA methylation in HCC. Disclosures: Kohichiroh Yasui – Grant/Research Support: AstraZeneca K. K., CHUGAI Pharmaceutical Co., Ltd., Dainippon Sumitomo Pharma Co., Ltd., Eisai Co., Ltd., FUJIFILM Medical Co., Ltd., Merck Serono, MSD K. K., Otsuka Pharmaceutical Co., Ltd. The following people have nothing to disclose: Osamu Dohi, Masayasu Jo, Yoshito Itoh Thioredoxin domain-containing protein 5 (TXNDC5) has been found to be associated GSI-IX with cancer development and growth. We investigated whether TXNDC5 gene polymorphisms are associated with hepatocellular carcinoma check details (HCC) in Korean male population. Seven SNPs were selected based on minor allele frequency (>0. 5). The SNPs consisted of three exonic (rs8643, rs7764128 and rs1043784) and four intronic SNPs (rs1225944, rs1225943, rs1225945 and rs1225958). We selected and assessed these SNPs in 160 HCC patients and 178 controls. Genetic data were analyzed using SNPAnalyzer Pro, SNPStats, and Haploview programs. Two SNPs of the TXNDC5 gene were found to be associated with the risk of HCC development.

The genotype frequency of rs1225944 was associated with HCC in the recessive model (CC/CT vs. TT, p=0. 43, Fisher’s exact p=0. 032, 〇R-0. 54, 95% CI=0. 112. 71). The genotype frequency of rs1225943 was associated with HCC in the codominant 2 (AA vs. CC, p=0. 07, Fisher’s exact p=0. 001, 〇R=0. 23, 95% CI=0. 05-1. 10), recessive (AA/AC vs. CC, p=0. 044, Fisher’s exact p=0. 001, 〇R=0. 25, 95% CI=0. 05-1. 17), and log-additive models (p=0. 08, Fisher’s exact p=0. 002, 〇R-0. 68, 95% CI=0. 44-1. 05). The haplotype CA and TC, consisting of rs1229544 and rs1225943, demonstrated a significant association with HCC. Our results suggest that TXNDC5 polymorphisms could be concerned with the development of HCC in the Korean male population.

It was found that miR-335, which is harbored within an intron of its protein-coding host gene, MEST, was down-regulated by check details aberrant promoter hypermethylation. The expression levels of miR-335 significantly correlated with those of MEST, supporting the notion that the intronic miR-335 is co-expressed with its host gene. The level of miR-335/MEST methylation was significantly higher in 18 (90%) out of 20 primary HCC tumors, compared to their non-tumor tissue counterparts (P<0. 001). The expression level of miR-335 was significantly lower in 25 (78%) out of 32 primary

HCC tumors, compared to their non-tumorous tissue counterparts (P=0. 001). Since miR-335 was identified as a metastasis suppressor miRNA in breast cancer, we examined the relationship between the expression levels of miR-335 and the presence of distant metastasis in these 32 primary HCCs. The expression

level of miR-335 was significantly lower in HCC tumors with distant metastasis than in those without distant metastasis (P=0. 02). In conclusion, our results indicate that expression of miR-335 is reduced by aberrant DNA methylation in HCC. Disclosures: Kohichiroh Yasui – Grant/Research Support: AstraZeneca K. K., CHUGAI Pharmaceutical Co., Ltd., Dainippon Sumitomo Pharma Co., Ltd., Eisai Co., Ltd., FUJIFILM Medical Co., Ltd., Merck Serono, MSD K. K., Otsuka Pharmaceutical Co., Ltd. The following people have nothing to disclose: Osamu Dohi, Masayasu Jo, Yoshito Itoh Thioredoxin domain-containing protein 5 (TXNDC5) has been found to be associated GPCR & G Protein inhibitor with cancer development and growth. We investigated whether TXNDC5 gene polymorphisms are associated with hepatocellular carcinoma selleck compound (HCC) in Korean male population. Seven SNPs were selected based on minor allele frequency (>0. 5). The SNPs consisted of three exonic (rs8643, rs7764128 and rs1043784) and four intronic SNPs (rs1225944, rs1225943, rs1225945 and rs1225958). We selected and assessed these SNPs in 160 HCC patients and 178 controls. Genetic data were analyzed using SNPAnalyzer Pro, SNPStats, and Haploview programs. Two SNPs of the TXNDC5 gene were found to be associated with the risk of HCC development.

The genotype frequency of rs1225944 was associated with HCC in the recessive model (CC/CT vs. TT, p=0. 43, Fisher’s exact p=0. 032, 〇R-0. 54, 95% CI=0. 112. 71). The genotype frequency of rs1225943 was associated with HCC in the codominant 2 (AA vs. CC, p=0. 07, Fisher’s exact p=0. 001, 〇R=0. 23, 95% CI=0. 05-1. 10), recessive (AA/AC vs. CC, p=0. 044, Fisher’s exact p=0. 001, 〇R=0. 25, 95% CI=0. 05-1. 17), and log-additive models (p=0. 08, Fisher’s exact p=0. 002, 〇R-0. 68, 95% CI=0. 44-1. 05). The haplotype CA and TC, consisting of rs1229544 and rs1225943, demonstrated a significant association with HCC. Our results suggest that TXNDC5 polymorphisms could be concerned with the development of HCC in the Korean male population.

These tumors comprise 2–5% of all EMPs and tend to be identified TAM Receptor inhibitor late unless an endoscopic examination is performed Methods: We report a rare case of gastric plasmacytoma that was treated with endoscopic resection and oral thalidomide therapy. A 70-year-old man was admitted because of indigestion. He had no specific medical history, and his laboratory results were unremarkable. Gastroscopy was performed, and a flat elevated lesion with focal erythematous changes was observed in the anterior wall of the antrum (Fig. 1). Biopsy showed atypical lymphocytes.

Endoscopic submucosal dissection was performed for the diagnosis and treatment by using an insulation-tipped knife (KD-610L; Olympus Tokyo, Japan) (Fig. 2). The resected specimen showed infiltration of plasma cells into the lamina propria; however, these cells did not extend deeply into the submucosal layer (Fig. 3). Erlotinib price Radiological and hematological evaluations, including bone marrow biopsy, were performed that showed no involvement of other organs. Finally, the patient was diagnosed with extramedullary

gastric plasmacytoma. Results: extramedullary plasmacytoma is a systemic disease, and hence, the patient was treated with oral thalidomide and dexamethasone. Follow-up gastroendoscopy was performed 6 months later, and the patient’s condition was found to

be stable. Conclusion: Gastric plasmacytoma is classified into nodular, infiltrative, ulcerative, and polypoid types, with the nodular type being the most common. Most gastric plasmacytomas are large and deeply infiltrating tumors with ulceration; however, in the early stage, tumor cells are limited to the mucosal and submucosal layers. Almost all patients with EMP undergo radiation therapy, surgery, or combination therapy (surgery and/or chemotherapy or irradiation). Key Word(s): 1. plasmacytoma; 2. ESD; 3. oral thalidomide; 4. H.pylori.; Presenting Author: YOUN HEE CHO Additional Authors: learn more SU JIN HONG, DAE YONG KIM, GYU SEOK CHO, GUI AE JEONG, HEE KYUNG KIM, JAE PIL HAN, MIN JIN KIM, BONG MIN KO, MOON SUNG LEE Corresponding Author: SU JIN HONG Affiliations: Soonchunhyang University College of Medicine Objective: The aim of this study was to compare the outcomes of ESD and gastrectomy according to the two indications for ESD (guideline criteria and expanded criteria). Methods: Between January 2004 and July 2007, 230 EGCs of 213 patients was enrolled in this study. Fifty-five patients were included in the guideline criteria (GC) group and 158 in the expanded criteria (EC) group. In the GC group, 35 patients underwent ESD, while 20 underwent gastrectomy. In the EC group, 107 patients underwent ESD, while 51 underwent gastrectomy.